Atecegatran metoxil

DB12507InvestigationalSmall molecule

Atecegatran metoxil has been used in trials studying the basic science and prevention of Nonvalvular Atrial Fibrillation, Persistent or Permanent Nonvalvular Atrial Fibrillation, and Persistent or Permanent Non-valvular Atrial Fibrillation.

Mechanism: Pharmacologically active on Prothrombin
Curator reviewed
Formula / weight: C₂₂H₂₃ClF₂N₄O₅ · 496.9 g/mol (avg)
Also known as: Atecegatran fexenetil
Code names: AZD-0837

Resolves to

Compound

UNII4GU1D587JVCAS433937-93-0PubChem9961205

Structure

InChIKeyXSNMGLZVFNDDPW-ZWKOTPCHSA-NSMILESCO\N=C(/N)C1=CC=C(CNC(=O)[C@@H]2CCN2C(=O)[C@H](O)C2=CC(OC(F)F)=CC(Cl)=C2)C=C1

Targets

P00734F2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Atecegatran metoxil, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account